Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections

Completed

• Conditions: Bone and Joint Infection; Antibiotic Reaction

• Registration Number: NCT03848104
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Cephamycin related to 2nd generation cephalosporins, the use of cefoxitin has long been limited to antibiotic prophylaxis. Because of its spectrum (sensitive staphylococci, enterobacteria including ESBL, streptococci, anaerobes), its stability and its low cost, it could be useful in curative bone and joint infections, especially in case of infection polymicrobial disease in patients for whom antibiotic alternative per os is limited.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2018-03-01
• Study Completion: 2018-04-01
• Status Verified: 2019-02
• Study First Submitted: 2019-02-19
• Study First Submitted QC: 2019-02-19
• Study First Posted: 2019-02-20
• Last Update Submitted: 2019-02-20
• Last Update Posted: 2019-02-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• patients havind had a bon and joint infeciton treated with cefoxitin in combination in continuous parenteral administration

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of Treatment Failure	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Secondary Outcome Measures

Name	Time	Method
Rate of use of this strategy	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	Descriptions of patients managed with this strategy

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Lyon, France